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Introduction: There are two types of Blood and Marrow trans-
plantation, which are performed in treating course of patients with
AML. Assessment of outcome, efﬁcacy and adverse effects of each
method is very important, in choosing the right protocol for
patients. Method: 138 transplanted patients 68 (49.3%) male and
70(50.7%) female, with diagnosis of AML were included in present
study during 1992-2003.The median age was 23 (ranged 3-58 yrs).
Seventy-three patients (52.9 %) patients received transplantation
as Allogeneic and 65 (47.1%) patients as Autologous. The source of
stem cells was Bone marrow in 40 (29 %), Peripheral blood in 97
(70.3 %) and BM plus PBSC in 1(0.7%) patients respectively.
Conditioning regimen for the Allogeneic was Busulphan 4 mg/kg
for 4 days plus Cyclophosphamide 60 mg/kg for 2 days and for
Autologous were ARA-C 100 mg/m2 /BD for 3 days plus VP16 500
mg/m2 for 3 days and Cyclophosphamide 60 mg/kg for 2 days.
Results: 50 out of 138 (36.2%) patients were died. The most
common leading causes of death were relapse in 26 (18.8%) cases
and the acute and chronic GVHD in 7(5%) cases. 10 years overall
survival (which was test by Kaplan-Meier) in Allogeneic and Au-
tologous transplantation was 52%, The relapse frequency in Allo-
geneic and Autologous was 11 % and 28 % respectively, which was
statistically signiﬁcant by Pearson Chi-Square test (P-value  0.01
and Odds Ratio  3.91). Patients in allogeneic and Autologous
groups were compared according to confounding factors such as
age, sex and stem cell source and there were not any signiﬁcant
difference. Conclusion: Despite a remarkable difference in relapse
frequency among these two groups we showed that there were not
any signiﬁcant difference in 10 years overall survival between
allogeneic and autologous cases. Furthermore we conclude that
Autologous PBSC transplantation is easier, cost effective and has
less morbidity.
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CR1 ACUTE MYELOID LEUKEMIA AND HLA-IDENTICAL ALLOGENEIC
TRANSPLANTATION (ASCT) PREPARED WITH REDUCED INTENSITY
REGIMEN (RIC): LEUKEMIA CONTROL REQUIRES ADEQUATE PRE
GRAFT CHEMOTHERAPY AND POST GRAFT GVHD
Faucher, C.1, Boiron, J.M.2, Mohty, M.1, Bay, J.O.3, Perreau, V.2,
Bilger, K.1, Vey, N.1, Stoppa, A.M.1, Coso, D.1, Ladaique, P.1, Ma-
raninchi, D.1, Blaise, D.1 1. Institut Paol-Calmettes, Marseille, France;
2. Hoˆpital Haut Leveˆque, Pessac, France; 3. Centre Jean Perrin, Cler-
mont Ferrand, France.
We report a prospective investigation of HLA identical ASCT
for pts with CR1 AML presenting contra-indications to standard
ASCT (age   50 and/or any comorbidity) and/or poor progno-
sis features. All pts received a RIC: Fludarabin (30mg/m2/j), Busul-
fan (8mg/kg) and thymoglobulin (2.5 mg/m2). This investigation
aimed to treat these pts with the best chemotherapy standard
followed with an allogeneic immunotherapy. Thus intensity of
chemotherapy prior to ASCT was increased stepwise and concom-
itantly immunosuppressive intensity of RIC was decreased. We
treated 26 pts (Age: 52 (26-60); M/F: 11/15) (age  50:19;
previous aspergillosis: 5, high WBC count: 6; secondary leukemia:
5; CR after 2 inductions: 4; poor cytogenetics: 8).All pts received
GVHD prophylaxis (CSA:15 ; CSAMTX:6; CSAMMF:5) and
either BM (10) or PBSC (16) graft). ASCT was performed without
any previous intensive chemotherapy (Group 1: N  5), after 1
cycle of high dose aracytine (3g/m2x2/jx4) idarubicin (12mg/m2/
jx2) (HIDAC) (Group 2; N  15) or after HIDAC and an autol-
ogous PBSCT prepared with melphalan (140mg/m2) (Group 3:
N  6). Allo PBSCT was performed 30 to 60 days after last
chemotherapy. Fludarabine was decreased from 180 to 120 mg/m2
and thymoglobulin from 10 to 2.5 mg/m2. On October 2003, with
a follow-up of 19 months (2-59), all pts engrafted achieving full
chimerism on day 60(30-90). 6 presented grade 2 aGVHD (Cu-
mulative incidence (CI)  23%) and 10 cGVHD (CI  42%).
Owerall 2 pts died from transplant toxicity (TRM) (TRM CI 
8%) and 10 relapsed (Relapse CI  38%) for an overall 2 year
survival (OS) probability of 57%. All pts in group 1 relapsed and 1
is long term survivor after second transplant. Of the 15 pts with
HIDAC alone, 5 relapsed (relapse CI: 33%), 1 died from GVHD
(TRMCI: 7%) for a 2 year OS 68%. Of the 6 pts with HIDAC and
Auto PBSCT, none relapsed and 1 died from GVHD. Relapse was
statistically associated with the absence of pre-graft intensive che-
motherapy (p  0.02), the use of higher dose (5-7.5 mg) of ATG
(p  0.003) and the absence of acute and chronic GVHD (p 
0.001). Longer survival was associated with the use pre-graft in-
tensive chemotherapy (p 0.04). We conclude that in a population
of high risk pts, RIC ASCT is associated with a low TRM and a
potent GVL effect if adequate prior chemotherapy is delivered and
conducts to high Os. Impact of prior Auto PBSCT seems beneﬁc
but needs longer follow-up and higher number of pts and is
presently evaluated.
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EVALUATION OF BONE MARROW TRANSPLANATION AND ARSENIC
TRIOXIDE IN THE TREATMENT OF AML M3 (AN EXPERIENCE IN IRAN)
Ghavamzadeh, A., Iravani, M., Jafari, M., Gholibeikian, S., Alimo-
ghaddam, K., Aghdami, N., Bahar, B., Mousavi, A. Hematology-
Oncology & BMT Research Center,Tehran University of Medical Sci-
ences, Tehran, Islamic Republic of Iran.
Background: Acute promyelocytic leukemia characterized by
t(15;17) and PML/RARa gene fusion. Material Methods: From
April 1993 till March 2003, 24 patients treated under BMT. Ten
Autologous and 14 allogeneic transplantations were done. Sixteen
peripheral bloods and 8 bone marrows were used as graft. Disease
status before transplantation was CR1: 21, CR2: 1 and 1st relapse:
2. Conditioning regimen in autologous transplantation was Ara–C
(1000 mg/m2/bd x 3 days)  Cyclophosphamide (60mg/kg x 2
days)  Etoposide (500mg/m2 x 3 days) and in allogeneic form the
main regimen was Busulfan (4mg/kg x 4 days) Cyclophospha-
mide (60mg/kg x 2 days). Other conditioning regimen, which used
in 2 patients in allogeneic transplantation, was Fludarabin (40mg/
m2/day/IV infusion x 5 days)  Busulfan (4mg/kg/day x 4 days).
Cyclosoporin and Methotrexate were used as prophylaxis drugs for
GVHD. The engraftment was evaluated with time of ANC 
500x108. Arsenic trioxide was used as other kind of treatment for
AMLm3 in 76 patients from May 2000 till March 2003. Sixty-
seven of patients were new case and 11 were in relapse state.
Arsenic trioxide (0.15 mg/kg/IV infusion for 2-4 hours) was used
from day of diagnosis till CR by morphologic criteria or till 60
days. Results: 70.8 % of patients (17/24) were in sustained CR
after BMT and 76.3% patients (64/76) achieved this state in arsenic
groups. Death occurred in 31.5% of patients (24/76) in arsenic and
20.8% of patients (5/24) in BMT group. The total 1, 3 and 5 years
overall survival (OS) and disease free survival (DFS) was 79.4%,
66.2%, 66.2% and 85%, 56.6% , 56.6% in BMT group respec-
tively. In Arsenic group the total 1 and 3 years OS and DFS was
70%, 63.1% and 89.6%and 73.9% respectively. Conclusion: Al-
though arsenic trioxide is a suitable and economical method for
treatment of AMLM3 but needs a long time for assessment the
efﬁcacy of it. We believe that bone marrow transplantation is a
curable alternative for these patients especially in high-risk form of
disease.
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